QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe
QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe sciprian@crf.org Wed, 10/30/2024 - 15:21 Caitlin E. Cox The inability of QFR to rival FFR for 1-year MACE
October 2024: Live From TCT 2024
October 2024: Live From TCT 2024 sciprian@crf.org Wed, 10/30/2024 - 15:14 Publish Date --> 4 hours 57 minutes ago Teaser --> Shelley Wood, Ajay K
Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions
Preprocedural AI-QCA Matches OCT-Guided PCI for Noncomplex Lesions sciprian@crf.org Wed, 10/30/2024 - 15:03 Yael L. Maxwell Several experts argue that AI-QCA is not a replace
TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation
TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation sciprian@crf.org Wed, 10/30/2024 - 14:42 Michael O'Riordan The benefit was confined to symptoms, bu
ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients
ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients sciprian@crf.org Wed, 10/30/2024 - 12:39 Todd Neale The result calls into question the prospects of FDA ap
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows sciprian@crf.org Tue, 10/29/2024 - 17:36 Michael O'Riordan The study conflicts with two prior trials sho
SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD
SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD sciprian@crf.org Tue, 10/29/2024 - 17:26 L.A. McKeown The data hint at sirolimus becoming a usefu
ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation
ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation sciprian@crf.org Tue, 10/29/2024 - 17:16 Yael L. Maxwell With the data under review by the FDA
In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI
In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI sciprian@crf.org Tue, 10/29/2024 - 13:34 Yael L. Maxwell Logistical challenges may impede heparin pretre
ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions
ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions sciprian@crf.org Tue, 10/29/2024 - 11:17 Yael L. Maxwell (UPDATED) Specialty technologies
PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE
PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE sciprian@crf.org Tue, 10/29/2024 - 11:52 Todd Neale The trial adds much-needed randomized data to an ar
ECLIPSE: Balloon Angioplasty as Good as Orbital Atherectomy in Calcified Lesions
ECLIPSE: Balloon Angioplasty as Good as Orbital Atherectomy in Calcified Lesions sciprian@crf.org Tue, 10/29/2024 - 11:17 Yael L. Maxwell Specialty technologies are still nee
TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR
TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR sciprian@crf.org Tue, 10/29/2024 - 10:05 Michael O'Riordan New analyses bolster the case for tricuspi
DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI
DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI sciprian@crf.org Tue, 10/29/2024 - 09:22 Todd Neale A clinically relevant question without a definiti
DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF
DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF sciprian@crf.org Mon, 10/28/2024 - 17:02 Caitlin E. Cox Why DCBs reduced MIs but had no impact on
More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact
More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact sciprian@crf.org Mon, 10/28/2024 - 15:33 Yael L. Maxwell Some argue new trial designs or devices
TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS
TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS sciprian@crf.org Mon, 10/28/2024 - 11:23 Todd Neale Select patients with moderate AS may benefit, but in ge
EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis
EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis sciprian@crf.org Mon, 10/28/2024 - 11:07 Michael O'Riordan In this underpowered trial, using CMR to g
EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS
EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS sciprian@crf.org Mon, 10/28/2024 - 10:51 L.A. McKeown While discussions about the lack of a mortality
New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding
New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding sciprian@crf.org Mon, 10/28/2024 - 08:33 Caitlin E. Cox Three secondary analyses clarified how the Impell
FDA Approves Dual-Energy System for AF Ablation
FDA Approves Dual-Energy System for AF Ablation sciprian@crf.org Mon, 10/28/2024 - 08:18 Todd Neale The Affera mapping and ablation system is the first on the market that can
Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes
Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes sciprian@crf.org Sun, 10/27/2024 - 17:43 L.A. McKeown Numerous opportunities exist for i
Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT
Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT sciprian@crf.org Sun, 10/27/2024 - 17:25 Michael O'Riordan Evolut Pro/Pro+ valves had the lowest rate of
LAAO Outcomes Similar Regardless of Operator’s Specialty
LAAO Outcomes Similar Regardless of Operator’s Specialty sciprian@crf.org Sun, 10/27/2024 - 16:29 Todd Neale EPs in the US do more LAAO procedures than interventional cardiol
Safety Retained When Fellows Lead Complex PCI Procedures
Safety Retained When Fellows Lead Complex PCI Procedures sciprian@crf.org Sun, 10/27/2024 - 14:31 Yael L. Maxwell The observational Welsh data show trainees perform slightly